Applied DNA Sciences, Inc. (NASDAQ:APDN ) Q1 2025 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Sanjay Hurry - Executive Director, IR & Corporate Communications Beth Jantzen - CFO James Hayward - Chairman & CEO Clay Shorrock - Chief Legal Officer & Executive Director, Business Development Judith Murrah - President & Secretary Conference Call Participants Eduardo Arce - H.C. Wainwright & Co Operator Good day, and welcome to the Applied DNA Sciences First Quarter Fiscal 2025 Financial Results.
Applied DNA Sciences (APDN) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $1.80 per share a year ago.
Applied DNA Sciences (APDN) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $5.20 per share a year ago.
8 May 2025 Date | | - Cons. EPS | - EPS |
6 Feb 2025 Date | | - Cons. EPS | - EPS |
5 Dec 2024 Date | | - Cons. EPS | - EPS |
18 Sep 2024 Date | | - Cons. EPS | - EPS |
8 Aug 2024 Date | | - Cons. EPS | 0.47 EPS |
8 May 2025 Date | | - Cons. EPS | - EPS |
6 Feb 2025 Date | | - Cons. EPS | - EPS |
5 Dec 2024 Date | | - Cons. EPS | - EPS |
18 Sep 2024 Date | | - Cons. EPS | - EPS |
8 Aug 2024 Date | | - Cons. EPS | 0.47 EPS |
Medical - Diagnostics & Research Industry | Healthcare Sector | James A. Hayward Sc.D. CEO | NASDAQ (CM) Exchange | 03815U300 Cusip |
US Country | 46 Employees | - Last Dividend | 2 Jun 2025 Last Split | 15 Jul 2003 IPO Date |
Applied DNA Sciences, Inc. is a biotechnology firm that focuses on the development and commercialization of DNA-based technologies across a diverse range of industries globally, including the Americas, Europe, Asia, and beyond. With its foundations laid in 1983 and a rebranding from Datalink Systems, Inc. to its current name in 2002, the company has established its headquarters in Stony Brook, New York. It caters to various sectors through its innovative DNA-focused solutions, operating across three primary segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services.
This segment centers on the development and commercialization of the LinearDNA platform. This groundbreaking technology facilitates the cell-free production of high-fidelity synthetic DNA sequences. These sequences are pivotal for nucleic acid-based therapeutics, offering a new frontier in the development of treatments and therapies.
Applied DNA Sciences provides a comprehensive range of clinical molecular diagnostics (MDx) testing and clinical laboratory services. This includes specialized COVID-19 testing services under the safeCircle trademark, which encompasses test scheduling, sample collection, and automated results reporting tailored for higher education institutions, private clients, and businesses. Additionally, the segment provides polymerase chain reaction (PCR) services for the production and detection of DNA and RNA, alongside MDx test kits, related supplies, and isotopic analysis testing services.
This division offers SigNature Molecular Tags, a technology designed to authenticate goods within large and complex supply chains. These tags are applied to materials like cotton, nutraceuticals, and various other products to corroborate their authenticity and origin. Furthermore, the segment provides portable DNA readers (SigNify) and consumable reagent test kits that assist in the verification process. Another noteworthy product is fiberTyping, a PCR-based DNA detection system used to identify the naturally occurring DNA sequences in products. This technology ensures product provenance authentication and maximizes supply chain security.